Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HLS TherapeuticsTSX:HLS +0.75%65 Equity-to-Asset is 0.45 as of Mar. 2026, which is 13% below its 10-year median of 0.52. GuruFocus rates TSX:HLS with a GF Score™ of 65/100 and a GF Value™ of C$4.49 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, HLS Therapeutics ranks worse than 70.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. HLS Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was C$80.36 Mil. HLS Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was C$179.85 Mil.
Therefore, HLS Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.45.
The historical rank and industry rank for HLS Therapeutics's Equity-to-Asset or its related term are showing as below:
TSX:HLS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43 Med: 0.52 Max: 0.98
Current: 0.45
During the past 13 years, the highest Equity to Asset Ratio of HLS Therapeutics was 0.98. The lowest was 0.43. And the median was 0.52.
TSX:HLS's Equity-to-Asset is ranked worse than 70.51% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs TSX:HLS: 0.45
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
HLS Therapeutics Equity-to-Asset Related Terms
HLS Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
HLS Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a Equity-to-Asset of 0.45 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on HLS Therapeutics and its competitors. This is 13% below median its historical median of 0.52. Over the past decade, HLS Therapeutics' Equity-to-Asset has ranged from 0.43 to 0.98. According to the industry distribution chart, HLS Therapeutics ranks #710 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 70.5%.
Is HLS Therapeutics' Equity-to-Asset too high?
HLS Therapeutics' current Equity-to-Asset of 0.45 is 13% below median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.98. The Drug Manufacturers industry median Equity-to-Asset is 0.61. HLS Therapeutics' value of 0.45 is 26.2% below this industry median. Based on the distribution chart, HLS Therapeutics ranks #710 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, HLS Therapeutics has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #710 out of 1007 companies for Equity-to-Asset. This places HLS Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.61. HLS Therapeutics' value of 0.45 is 26.2% below this benchmark. Historically, HLS Therapeutics' own Equity-to-Asset has ranged from 0.43 to 0.98 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.61, HLS Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current Equity-to-Asset of 0.45 is 26.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current Equity-to-Asset is 0.45, which is 13% below median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Modestly Undervalued. The stock's GF Value™ is C$4.49, compared to a current price of C$4.03 — trading 10.2% below its estimated fair value. The current Equity-to-Asset is 0.45, which is 13% below median its 10-year median of 0.52 and 26.2% below the Drug Manufacturers industry median of 0.61. HLS Therapeutics' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Equity-to-Asset is 0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.03 is trading 10.2% below its estimated GF Value™ of C$4.49.
GuruFocus considers HLS Therapeutics to be Modestly Undervalued.
Key valuation signals for TSX:HLS:
Equity-to-Asset: 0.45 (13% below median its 10-year median of 0.52)
GF Value™: C$4.49 vs. price of C$4.03 (10.2% below fair value)
Industry Position: 26.2% below the Drug Manufacturers median (#710 of 1007)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
65GF Score
Get the complete analysis for TSX:HLS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
